Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Case Report Volume 4 Issue 10

Cannabinoid Efficacy in Vanishing White Matter Disease: A Case Report

Giulia Galli1*, Virgilio E1,2, Naldi P1, Fornaro R4, Baricich A5, Vecchio D1,3 and Cantello R1,3

1Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliera-Universitaria Maggiore della Carità, Novara, Italy
2Phd Program in Medical Sciences and Biotechnologies, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
3Interdisciplinary Research Center of Autoimmune Diseases (IRCAD), Department of Health Sciences, University of Piemonte Orientale, Novara, Italy
4Neurosurgery Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliera-Universitaria Maggiore della Carità, Novara, Italy
5Physical Medicine and Rehabilitation, Department of Translational Medicine, University of Piemonte Orientale, San Giuliano Hospital, Novara, Italy

*Corresponding Author: Giulia Galli, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Azienda Ospedaliera-Universitaria Maggiore della Carità, Novara, Italy.

Received: September 08, 2021; Published: September 29, 2021

×

Abstract

Background: An oromucosal spray formulation (Sativex®) containing delta-9-tetrahydrocannabinol and cannabidiol is indicated to treat unresponsive severe spasticity in Multiple Sclerosis. A lot of clinical trials are underway demonstrating a potential role as supplemental therapy in various neurological conditions, in particular addressing pain and spasticity in adults and children.

Case Report: We present a 30-year-old man who was diagnosed with Vanishing White Matter disease at the age of 9. VWMS is a rare autosomal recessive syndrome characterized by progressive white matter deterioration, due to mutations in either one of the five subunits of eukaryotic translation initiation factor eIF2B. The classic phenotype includes ataxia, spasticity, cognitive decline and seizures from early childhood. As young adult, our patient showed severe spastic tetraparesis with spasms and neck muscle stiffness with right laterocollis. Clonazepam, baclofen and botulinum injections were tried with poor results. THC-CBD spray at the dose of 4 sprays per day improved muscular pain, spasms and night sleep, reduced modestly spasticity and caused only mild drowsiness. To maximize the spasticity treatment, a baclofen intrathecal infusion pump was positioned, but Sativex® was continued after surgery for its positive effect on patient’s quality of life.

Conclusion: To our knowledge, this is the first time that THC-CBD has been in an adult patient with VWM. The treatment was well-tolerated, act moderately on spasticity but muscular spasm and night sleep improved as well as quality of life.

Keywords: Vanishing White Matter Disease; Leukoencephalopathy; Spasticity Treatment; THC-CBD Spray; Cannabinoids

×

Citation

Citation: Giulia Galli., et al. “Cannabinoid Efficacy in Vanishing White Matter Disease: A Case Report”. Acta Scientific Neurology 4.10 (2021):.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US